Application of Intravitreal Conbercept Injection as a Primary Treatment for Exudative Circumscribed Choroidal Haemangioma — IVCCCH  

Circumscribed Choroidal Haemangioma Clinical Trial

Official title: Application of Intravitreal Conbercept Injection as a Primary Treatment for Exudative Circumscribed Choroidal Haemangioma: Short-term Follow-up of Anatomical and Functional Responses

Status Recruiting

Clinical Trial Summary

The aim of this study was to investigate the safety and effectiveness of application of intravitreal conbercept injection as the primary treatment for exudative circumscribed choroidal haemangioma.

Clinical Trial Description

This prospective clinical trial aims to evaluate the safety and effectiveness study of intravitreal conbercept injection as the primary treatment for exudative circumscribed choroidal haemangioma: (1)To evaluate therapeutic effect (including both anatomical and functional responses to intravitreal conbercept injection) of intravitreal conbercept injectionfor exudative circumscribed choroidal haemangioma; (2)To evaluate the safety (including side effects of the eye as well as side effects of system) of intravitreal conbercept injection for exudative circumscribed choroidal haemangioma. ;

Related Conditions & MeSH terms

• Circumscribed Choroidal Haemangioma
• Hemangioma

• NCT number: NCT03973125
• Study type: Interventional
• Source: Sun Yat-sen University
• Contact: Kunbei Lai
• Phone: 8602087331366
• Email: laikb@163.com
• Status: Recruiting
• Phase: Early Phase 1
• Start date: August 28, 2014
• Completion date: January 1, 2020